WO2008152654A1 - Protéines hybrides du charbon, compositions et leurs applications - Google Patents
Protéines hybrides du charbon, compositions et leurs applications Download PDFInfo
- Publication number
- WO2008152654A1 WO2008152654A1 PCT/IN2008/000368 IN2008000368W WO2008152654A1 WO 2008152654 A1 WO2008152654 A1 WO 2008152654A1 IN 2008000368 W IN2008000368 W IN 2008000368W WO 2008152654 A1 WO2008152654 A1 WO 2008152654A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- anthrax
- fusion proteins
- recombinant fusion
- optionally
- Prior art date
Links
- 241000193738 Bacillus anthracis Species 0.000 title claims abstract description 147
- 239000000203 mixture Substances 0.000 title claims abstract description 67
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 34
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 34
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 144
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 120
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 94
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 94
- 231100000518 lethal Toxicity 0.000 claims abstract description 43
- 230000001665 lethal effect Effects 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 39
- 206010030113 Oedema Diseases 0.000 claims abstract description 37
- 230000008569 process Effects 0.000 claims abstract description 23
- 239000002671 adjuvant Substances 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 208000015181 infectious disease Diseases 0.000 claims abstract description 19
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 17
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 13
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 13
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 13
- 229940021747 therapeutic vaccine Drugs 0.000 claims abstract description 5
- 101710194807 Protective antigen Proteins 0.000 claims description 102
- 210000004027 cell Anatomy 0.000 claims description 43
- 230000014509 gene expression Effects 0.000 claims description 31
- 230000002163 immunogen Effects 0.000 claims description 31
- 229960005486 vaccine Drugs 0.000 claims description 31
- 239000013604 expression vector Substances 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 18
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 16
- 241000588724 Escherichia coli Species 0.000 claims description 14
- 230000029087 digestion Effects 0.000 claims description 13
- 238000000855 fermentation Methods 0.000 claims description 13
- 230000004151 fermentation Effects 0.000 claims description 13
- 238000011161 development Methods 0.000 claims description 12
- 229930027917 kanamycin Natural products 0.000 claims description 12
- 229960000318 kanamycin Drugs 0.000 claims description 12
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 12
- 229930182823 kanamycin A Natural products 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000000746 purification Methods 0.000 claims description 11
- 229940065181 bacillus anthracis Drugs 0.000 claims description 10
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 8
- 229940024606 amino acid Drugs 0.000 claims description 8
- 239000006142 Luria-Bertani Agar Substances 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 7
- 229920001817 Agar Polymers 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000008272 agar Substances 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 6
- 230000003115 biocidal effect Effects 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 230000009466 transformation Effects 0.000 claims description 6
- 230000001131 transforming effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims description 4
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 claims description 4
- 238000012512 characterization method Methods 0.000 claims description 4
- 230000004797 therapeutic response Effects 0.000 claims description 4
- 101150105115 PA gene Proteins 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 claims description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- 101000870242 Bacillus phage Nf Tail knob protein gp9 Proteins 0.000 claims description 2
- 101100327537 Caenorhabditis elegans cgp-1 gene Proteins 0.000 claims description 2
- 108010039939 Cell Wall Skeleton Proteins 0.000 claims description 2
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 claims description 2
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 229960003767 alanine Drugs 0.000 claims description 2
- 210000004520 cell wall skeleton Anatomy 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 claims description 2
- 229960005225 mifamurtide Drugs 0.000 claims description 2
- 108700007621 mifamurtide Proteins 0.000 claims description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 108010094020 polyglycine Proteins 0.000 claims description 2
- 229920000232 polyglycine polymer Polymers 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 claims description 2
- 229940021993 prophylactic vaccine Drugs 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 87
- 108020004414 DNA Proteins 0.000 description 19
- 230000027455 binding Effects 0.000 description 16
- 108700012359 toxins Proteins 0.000 description 13
- 239000000443 aerosol Substances 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 208000022338 anthrax infection Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000003000 inclusion body Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010017931 gastrointestinal anthrax Diseases 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229940124899 Biothrax Drugs 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 101800001707 Spacer peptide Proteins 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000009449 inhalation anthrax Diseases 0.000 description 2
- 208000023372 inhalational anthrax Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 239000007922 nasal spray Substances 0.000 description 2
- 229940097496 nasal spray Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 101500000960 Bacillus anthracis Protective antigen PA-63 Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 241000654838 Exosporium Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 102000004961 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 238000012369 In process control Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 206010035667 Pneumonia anthrax Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 229960000754 anthrax vaccine adsorbed Drugs 0.000 description 1
- 229960005447 anthrax vaccines Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 201000004836 cutaneous anthrax Diseases 0.000 description 1
- 101150084863 cya gene Proteins 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000012444 downstream purification process Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010965 in-process control Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 101150005373 lef gene Proteins 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000026447 protein localization Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011537 solubilization buffer Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000010408 sweeping Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Abstract
La présente invention concerne des protéines hybrides recombinées du charbon, des procédés destinés à la préparation de ces protéines et des compositions contenant ces protéines. Plus précisément, les protéines hybrides recombinées de la présente invention comprennent la protéine du facteur oedème (EF), de préférence une protéine du facteur oedème (EF) native ou une protéine du facteur oedème (EFm) mutée ou une protéine du facteur oedème (EFn) tronquée ou, mieux encore, une protéine du facteur oedème (EFn) tronquée et la protéine du facteur létal (LF), de préférence une protéine du facteur létal (LF) native ou une protéine du facteur létal (LFm) mutée ou une protéine du facteur létal (LFn) tronquée ou, mieux encore, une protéine du facteur létal (LFn) tronquée, éventuellement avec un lieur. L'invention concerne également des acides nucléiques codant pour les protéines hybrides de la présente invention. La présente invention concerne également une composition contre une infection par B. anthracis, comprenant la protéine hybride recombinée du charbon mélangée à un antigène protecteur (PA) natif ou adulte ou muté, et éventuellement à un ou plusieurs adjuvants, pouvant être utile comme vaccin thérapeutique et/ou préventif contre le charbon, avant ou après une exposition à la bactérie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1251DE2007 | 2007-06-11 | ||
IN1251/DEL/2007 | 2007-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008152654A1 true WO2008152654A1 (fr) | 2008-12-18 |
Family
ID=40129293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2008/000368 WO2008152654A1 (fr) | 2007-06-11 | 2008-06-11 | Protéines hybrides du charbon, compositions et leurs applications |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008152654A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103520717A (zh) * | 2013-09-02 | 2014-01-22 | 中山大学 | 丙氨酸作为疫苗佐剂的应用 |
US9616117B2 (en) | 2008-10-02 | 2017-04-11 | Pharmathene, Inc. | Anthrax vaccine formulation and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003048390A1 (fr) * | 2001-12-05 | 2003-06-12 | Rakesh Bhatnagar | Procede de preparation d'un vaccin non toxique contre l'anthrax |
US20040028695A1 (en) * | 2002-04-12 | 2004-02-12 | Sukjoon Park | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis |
WO2008048344A2 (fr) * | 2006-02-13 | 2008-04-24 | Fraunhofer Usa, Inc. | Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes |
-
2008
- 2008-06-11 WO PCT/IN2008/000368 patent/WO2008152654A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003048390A1 (fr) * | 2001-12-05 | 2003-06-12 | Rakesh Bhatnagar | Procede de preparation d'un vaccin non toxique contre l'anthrax |
US20040028695A1 (en) * | 2002-04-12 | 2004-02-12 | Sukjoon Park | Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis |
WO2008048344A2 (fr) * | 2006-02-13 | 2008-04-24 | Fraunhofer Usa, Inc. | Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9616117B2 (en) | 2008-10-02 | 2017-04-11 | Pharmathene, Inc. | Anthrax vaccine formulation and uses thereof |
CN103520717A (zh) * | 2013-09-02 | 2014-01-22 | 中山大学 | 丙氨酸作为疫苗佐剂的应用 |
CN103520717B (zh) * | 2013-09-02 | 2015-11-18 | 中山大学 | 丙氨酸作为疫苗佐剂的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7355027B2 (en) | Bacillus anthracis protective antigen | |
McBride et al. | Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers | |
EP1962890B1 (fr) | Composition immunogene | |
JP6084631B2 (ja) | Clostridiumdifficile毒素ベースのワクチン | |
JP2009515831A (ja) | ペスト菌(Yersiniapestis)抗原を含む組成物 | |
JP2012501959A (ja) | Yersiniapestis抗原を含む組成物 | |
US7947268B2 (en) | Salmonella based oral vaccines for anthrax | |
US20020197272A1 (en) | Methods for protecting against lethal infection with bacillus anthracis | |
IL118578A (en) | Hybrid nucleic acid molecule for expression of lipoproteins | |
MX2015002485A (es) | Polipeptidos de clostridium difficile como vacuna. | |
US20050112145A1 (en) | Anthrax antigenic compositions | |
JP2012510289A (ja) | グルタミルtRNA合成酵素(GtS)フラグメント | |
KR101130884B1 (ko) | 패혈증 비브리오균의 플라젤린과 병원체의 항원 단백질을 융합시켜 제조한 재조합 융합 단백질 및 이를 유효성분으로 포함하는 점막 투여용 백신 | |
WO2008152654A1 (fr) | Protéines hybrides du charbon, compositions et leurs applications | |
WO2008152655A1 (fr) | Protéines hybrides du charbon, compositions et leurs applications | |
US8323927B2 (en) | Preparation of protective antigen | |
US20130149330A1 (en) | Pharmaceutical compositions and methods of blocking bacillus anthracis | |
WO2020078420A1 (fr) | Préparations immunogènes et procédés contre une infection par clostridium difficile | |
US20060165729A1 (en) | Protein from photobacterium damselae and use thereof | |
KR102100503B1 (ko) | 개선된 고스트 장관독소형 대장균를 유효성분으로 포함하는 돼지 대장균증의 예방 또는 치료용 백신 조성물 | |
JP2019531100A (ja) | ワクチン構築物およびブドウ球菌感染症に対するその使用 | |
US9233150B2 (en) | Combination vaccine | |
US10293040B1 (en) | Pharmaceutical compositions and methods of blocking Bacillus anthracis | |
US9610341B2 (en) | Bacterial vaccine | |
AU2002341182A1 (en) | Anthrax antigenic compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08763753 Country of ref document: EP Kind code of ref document: A1 |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08763753 Country of ref document: EP Kind code of ref document: A1 |